Eric Liebler, Founder and Former President of Nautilus Neurosciences, Joins ElectroCore
MORRIS PLAINS, N.J., Jan. 9, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious neurological conditions and bronchoconstriction, announced today that Eric Liebler, co-founder and former President of Nautilus Neurosciences, Inc., has joined ElectroCore as VP, Scientific, Medical and Governmental Affairs.
Mr. Liebler brings more than 20 years of neurological industry and association experience to ElectroCore. In 2009, he co-founded Nautilus Neurosciences, a neurology-focused specialty pharmaceutical company focused on identifying and developing drugs benefitting those affected by neurological disorders, to market Cambia® for the treatment of acute migraine. At Nautilus, Mr. Liebler was involved in all facets of the company's organization and early success including initial funding, product commercialization and sales and marketing.
"Eric's deep expertise across many facets of neurology will be a valuable asset to ElectroCore as we continue to grow in the field of non-invasive vagal stimulation," said JP Errico, CEO of ElectroCore. "His industry experience and ability to thrive in an entrepreneurial setting will benefit ElectroCore as we explore nVNS across several serious neurological conditions."
Mr. Liebler has held leadership positions at Elan, Amarin, Enzon Pharmaceuticals, Questcor Pharmaceuticals, and Pharmacopeia. He founded Nisola LLC, an advocacy and business strategy-consulting firm focused on serving clients in the field of neurology, and sat on the Board of Trustees of the American Academy of Neurology Foundation (now the American Brain Foundation) for more than a decade. Mr. Liebler began his career at Athena Neurosciences, a pioneer in the development of neurology drugs.
"ElectroCore's nVNS devices have the potential to be game-changers in a broad range of serious conditions," said Liebler. "I'm thrilled to join a team that's committed to bringing meaningful treatment advances to patients suffering from migraines, cluster headaches and epilepsy."
ElectroCore is a healthcare company focused on non-invasive neuromodulation therapies for the treatment of diseases and disorders. The company has developed non-invasive Vagal Nerve Simulation (nVNS) therapies intended to treat and/or prevent symptoms of a number of highly prevalent and disabling conditions. ElectroCore currently has three commercial products on the market: GammaCore®, AlphaCore®, and GammaCore VET™. The company is headquartered in Morris Plains, NJ, with international offices in Stockholm, Sweden, Hamilton, Bermuda, and Sydney, Australia.
For more information, visit: http://www.electrocoremedical.com/.
SOURCE ElectroCore Medical